-
公开(公告)号：US20250154121A1
公开(公告)日：2025-05-15
申请号：US18833602
申请日：2023-01-19
Applicant: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES , INSTITUTE OF CHINESE MATERIA MEDICA, CHINA ACADEMY OF CHINESE MEDICAL SCIENCES
Inventor： Chenggang HUANG , Xiaolan CUI , Yang XIE , Xiaoting TIAN , Shanshan GUO , Zhixiong LI , Yingjie GAO
IPC: C07D311/36 , A61K31/352 , A61P31/14 , A61P31/16
Abstract: A novel compound represented by general formula I, a pharmaceutically acceptable salt thereof, a solvate, a stereoisomer including mixtures thereof in all ratios, and a pharmaceutical composition containing the compound are provided. Also provided are preparation method for the compound, and applications of the compound, the pharmaceutically acceptable salt thereof, the solvate, and the stereoisomer including the mixtures in all ratios, and in particular to a use of the compound in the preparation of antiviral drugs.
-
公开(公告)号：US20250127751A1
公开(公告)日：2025-04-24
申请号：US18916812
申请日：2024-10-16
Inventor： Aihua Liang , Jingzhuo Tian , Chenyue Liu
IPC: A61K31/285 , A61K31/404 , A61K31/7076 , A61P35/00
Abstract: The disclosure belongs to the technical field of medicine, and specifically discloses a traditional Chinese medicine compound preparation for tumors and application thereof. The traditional Chinese medicine compound preparation includes dimethylarsenic acid, indirubin and cordycepin in a concentration ratio of (1-20):(1-10):(1-40). The traditional Chinese medicine compound preparation of the disclosure can be used for treating kinds of tumors, including leukemia, gastric cancer, lung cancer, glioma, papillary thyroid carcinoma, growth hormone adenoma, pituitary adenoma, myeloma, and other malignant tumors. The traditional Chinese medicine compound preparation has significant treatment effect, high safety, and good development prospects.
-
公开(公告)号：US12252687B2
公开(公告)日：2025-03-18
申请号：US18456333
申请日：2023-08-25
Applicant: Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences , Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences
Inventor： Xueli Zhang , Luqi Huang , Zhubo Dai , Dong Wang , Lili Zhang , Juan Guo , Yi Liu
Abstract: Provided is a recombinant yeast expressing germacrene A synthetase or a fusion protein thereof, wherein the fusion protein is germacrene A synthetase and farnesyl pyrophosphate synthase. The recombinant yeast improves the yield of germacrene A, and is suitable for the industrialized production of β-elemene and/or germacrene A.
-
公开(公告)号：US11008360B2
公开(公告)日：2021-05-18
申请号：US16620015
申请日：2018-05-15
Inventor： An Liu , Jintang Cheng , Cong Guo , Jun Zhang , Chang Chen
IPC: C07H19/044
Abstract: The present invention relates to an indoleacetic acid derivative and a preparation method and pharmaceutical use thereof. In particular, the present invention relates to a compound shown in general formula (I), a preparation method thereof, a pharmaceutical composition comprising the same, and a use thereof as a cough suppressant in treating a disease such as a cough. The definition of each substituent in the general formula (I) is the same as the definition in the specification.
-
公开(公告)号：US12091696B2
公开(公告)日：2024-09-17
申请号：US18447649
申请日：2023-08-10
Inventor： Sha Chen , Yuetong Yu
CPC classification number: C12P17/12 , C12N1/205 , C12N9/1007 , C12N15/52 , C12N15/70 , C12P13/02 , C12P17/182 , C12R2001/19
Abstract: The present disclosure provides an O-methyltransferase protein with a highly specific catalytic function for multiple benzylisoquinoline alkaloids (BIAs) parent nuclei and an encoding gene and use thereof. Compared with wild-type O-methyltransferase, the O-methyltransferase protein (SEQ ID NO: 2) shows an enhanced enzymatic activity and a wider substrate scope. The O-methyltransferase protein can catalyze O-methylation of backbones from three BIAs, including monobenzylisoquinolines (norcoclaurine, coclaurine, and N-methylcoclaurine), aporphines (asimilobine and N-methylasimilobine), and protoberberines (scoulerine and tetrahydrocolumbamine). Meanwhile, this O-methyltransferase protein is highly regioselective for each backbone. The O-methyltransferase protein catalyzes methylation of the monobenzylisoquinolines at 6-OH and 7-OH, is only active on 6-OH of the backbone of the aporphines, and mainly catalyzes methylation of the protoberberines at 2-OH. Moreover, the O-methyltransferase protein has a stronger catalytic activity and can be used as a biocatalyst for the semi-synthesis of related compounds.
-
Patent Agency Ranking
公开(公告)号：US20240052388A1
公开(公告)日：2024-02-15
申请号：US18447649
申请日：2023-08-10
Inventor： Sha CHEN , Yuetong YU
CPC classification number: C12P17/12 , C12N9/1007 , C12P17/182 , C12N1/205 , C12P13/02 , C12N15/70 , C12N15/52 , C12R2001/19
Abstract: The present disclosure provides an O-methyltransferase protein with a highly specific catalytic function for multiple benzylisoquinoline alkaloids (BIAs) parent nuclei and an encoding gene and use thereof. Compared with wild-type O-methyltransferase, the O-methyltransferase protein (SEQ ID NO: 2) shows an enhanced enzymatic activity and a wider substrate scope. The O-methyltransferase protein can catalyze O-methylation of backbones from three BIAs, including monobenzylisoquinolines (norcoclaurine, coclaurine, and N-methylcoclaurine), aporphines (asimilobine and N-methylasimilobine), and protoberberines (scoulerine and tetrahydrocolumbamine). Meanwhile, this O-methyltransferase protein is highly regioselective for each backbone. The O-methyltransferase protein catalyzes methylation of the monobenzylisoquinolines at 6-OH and 7-OH, is only active on 6-OH of the backbone of the aporphines, and mainly catalyzes methylation of the protoberberines at 2-OH. Moreover, the O-methyltransferase protein has a stronger catalytic activity and can be used as a biocatalyst for the semi-synthesis of related compounds.
-
7.发明公开公开(公告)号：US20240358733A1
公开(公告)日：2024-10-31
申请号：US18646814
申请日：2024-04-26
Inventor： Aihua Liang , Jing Meng , Jingzhuo Tian
IPC: A61K31/7048 , A61P7/00 , A61P13/12
CPC classification number: A61K31/7048 , A61P7/00 , A61P13/12
Abstract: The present disclosure herein belongs to the field of biomedicine, and discloses an application of typhaneoside in preparation of a medicine for uric acid-lowering and/or hyperuricemic kidney injury, wherein the typhaneoside is the sole active ingredient in the preparation of a medicine for uric acid-lowering and/or hyperuricemic kidney injury. The typhaneoside being able to significantly reduce the blood uric acid level, at the same time, the typhaneoside is able to improve hyperuricemic kidney injury by lowering the uric acid deposition in the kidneys. As a drug for anti-hyperuricemia and improving hyperuricemic kidney injury, typhaneoside shows significant application prospects and is widely used in the market.
-
8.发明公开公开(公告)号：US20240358717A1
公开(公告)日：2024-10-31
申请号：US18646823
申请日：2024-04-26
Inventor： Jingzhuo Tian , Aihua Liang , Jing Meng
IPC: A61K31/575 , A61P13/02
CPC classification number: A61K31/575 , A61P13/02
Abstract: The present disclosure provides the application of β-ecdysterone in preparation of a medicine for uric acid-lowering and/or hyperuricemic kidney injury. β-ecdysterone or/and isomers thereof, or/and pharmaceutically acceptable salts, esters or/and prodrugs thereof are the sole active components in the drug, which further comprises a pharmaceutically acceptable carrier thereof; on the one hand, it has a uric acid-lowering effect on hyperuricemia, and on the other hand, it can reduce blood creatinine and urea nitrogen, reduce urate crystals, and thus improve kidney injury in hyperuricemia; it also has the effect of reducing the degree of kidney tubular dilation and wall thinning, as well as reducing the renal epithelial cell detachment. Compared with the prior art, the active ingredient β-ecdysterone of the present disclosure can not only reduce uric acid but also protect the kidney injury of hyperuricemia, and provides a new use for the preparation of drugs by β-ecdysterone.
-
9.发明公开公开(公告)号：US20230372288A1
公开(公告)日：2023-11-23
申请号：US18226226
申请日：2023-07-25
Inventor： Aihua Liang , Lianmei Wang
Abstract: The present application discloses an application of an aristolochic acid IVa in preparation of an antihistamine or a drug for treating pneumonia, and belongs to the technical field of new medicine uses. It uses the aristolochic acid IVa and a pharmaceutically acceptable salt thereof as active components, the antihistamine effect may be achieved by inhibiting the vascular permeability on the one hand, and the pneumonia treatment may be achieved by reducing the amount of tissue inflammation exudation on the other hand. Compared with existing technologies, the active ingredient aristolochic acid IVa of the present application does not have apparent toxicity and is quite safe, so a new direction for an application of a traditional Chinese medicine containing the aristolochic acid is provided.
-
公开(公告)号：US11421199B2
公开(公告)日：2022-08-23
申请号：US16347552
申请日：2017-11-02
Applicant: Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences , Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences
Inventor： Xueli Zhang , Luqi Huang , Zhubo Dai , Dong Wang , Lili Zhang , Juan Guo , Yi Liu
Abstract: Provided is a recombinant yeast expressing germacrene A synthetase or a fusion protein thereof, wherein the fusion protein is germacrene A synthetase and farnesyl pyrophosphate synthase. The recombinant yeast improves the yield of germacrene A, and is suitable for the industrialized production of β-elemene and/or germacrene A.
-
-
-
-
-
-
-
-
-
Search Results
11
records
(took 0.021 seconds)
